Sökning: "Hypertension drug therapy"

Visar resultat 1 - 5 av 14 avhandlingar innehållade orden Hypertension drug therapy.

  1. 1. Hypertension, atherosclerosis and fracture risk - observational investigations with focus on antihypertensive therapy

    Författare :Tove Bokrantz; Göteborgs universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; epidemiology; hypertension; antihypertensive agents; fractures; peripheral arterial disease; bone density;

    Sammanfattning : Aim: To investigate associations between hypertension, arteriosclerotic disease, and fracture risk in adults and the elderly, with a certain focus on how specific antihypertensive drug treatments in patients with high blood pressure might affect the risk for fractures. Methods and results: In Study I and II, the associations between different antihypertensive treatments and fracture risk were investigated in a cohort of about 60. LÄS MER

  3. 2. Inhibition of PDGF receptor signaling in tumor stroma : Effects on interstitial hypertension, drug uptake and therapeutic response

    Författare :Kristian Pietras; Sven Påhlman; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; PDGF; tumor; stroma; tyrosine kinase inhibitor; combination therapy; Onkologi; Oncology; Onkologi; molekylär cellbiologi; Molecular Cellbiology;

    Sammanfattning : The role of platelet-derived growth factor (PDGF) in malignancies involves both autocrine and paracrine stimulation of cells within the tumor. The interstitial fluid pressure (IFP) is one of the forces that govern the transvascular flow of fluids. LÄS MER

  4. 3. Pharmacometric Models for Biomarkers, Side Effects and Efficacy in Anticancer Drug Therapy

    Författare :Emma K. Hansson; Lena Friberg; Mats O Karlsson; Charlotte Kloft; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics; Pharmacodynamics; Oncology; Febrile Neutropenia; GIST; Sunitinib; PHARMACY; FARMACI; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Sammanfattning : New approaches quantifying the effect of treatment are needed in oncology to improve the drug development process and to enable treatment optimization for existing therapies. This thesis focuses on the development of pharmacometric models for biomarkers, side effects and efficacy in order to identify predictors of clinical response in anti-cancer drug therapy. LÄS MER

  5. 4. Vardenafil and methylarginines in pulmonary hypertension

    Författare :Anna Sandqvist; Gerhard Wikström; Jörn Schneede; Amrita Ahluwalia; Umeå universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; vardenafil; pulmonary hypertension; pharmacokinetics; haemodynamics; right heart catheterization; adenosine; dimethylarginines; phosphodiesterase type 5 inhibitors; endothelin receptor antagonists; klinisk farmakologi; Clinical Pharmacology;

    Sammanfattning : Background: Pulmonary hypertension (PH) is a rare condition characterized by endothelial dysfunction and vascular remodelling, leading to increased pulmonary vascular resistance (PVR) and right ventricular heart failure. Endothelial dysfunction is associated with an imbalance between vasoconstrictor compounds, such as endothelin and thromboxane A2, and vasodilator compounds, such as prostacyclin and nitric oxide (NO). LÄS MER

  7. 5. Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment

    Författare :Pär Hallberg; Håkan Melhus; Ann-Christine Syvänen; Lars Lind; Jiguang Wang; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Molecular medicine; pharmacogenomics; irbesartan; atenolol; hypertension; digoxin; RIKS-HIA; atrial fibrillation; heart failure; Molekylärmedicin; Molecular medicine genetics and pathology ; Molekylär medicin genetik och patologi ;

    Sammanfattning : In Part I we found that the CYP2C9 genotype appears to influence the diastolic blood pressure response to the angiotensin II-receptor antagonist irbesartan in patients with hypertension and left ventricular hypertrophy. Those with the *1/*2 genotype (slower metabolism) responded better than those with the *1/*1 genotype (normal metabolism), likely due to a slower elimination of the drug. LÄS MER